Coronary Physiology in multi-vessel disease (including LMCA & pre-CABG)
This session will focus on the evidence base for utilisation of coronary physiology in complex anatomical substrate. It shall principally focus on multi-vessel and left main stem coronary artery disease.
This program is made possible by an unrestricted educational grant from Abbott. The technologies been discussed may not be approved for use in your country.
Dr. Ozan Demir is an Interventional Cardiology Fellow and Clinical Research Fellow at St Thomas’...Read More
Dr. Ozan Demir is an Interventional Cardiology Fellow and Clinical Research Fellow at St Thomas’ Hospital and King’s College London, where he is currently undertaking a PhD in coronary physiology under the supervision of Professor Divaka Perera. He studied Medicine at King’s College London and trained in London prior to undertaking Interventional Cardiology Fellowships at Hammersmith Hospital, London and San Raffaele, Milano. During his Fellowship in Milano, under the supervision of Professor Antonio Colombo and Professor Azeem Latib, he undertook an MSc in Interventional Cardiology at the Università Vita-Salute San Raffaele. He is currently involved in various clinical research studies on coronary physiology.Show Less
Asst. Prof. Pawel Gasior is an interventional cardiology fellow in Division of Cardiology and...Read More
Asst. Prof. Pawel Gasior is an interventional cardiology fellow in Division of Cardiology and Structural Heart Diseases, Medical University of Silesia in Poland. He is a Fellow of the European Society of Cardiology and the currently act as co-chair of the EAPCI New Initiatives for Young Interventionalists Committee. Following graduation from Medical University of Silesia he undertook research fellowship at Cardiovascular Research Foundation in New York under supervision of Dr. Juan Granada. Besides clinical medicine, he is also engaged in both clinical and preclinical research on intravascular imaging, new intravascular technologies, coronary physiology and coronary artery disease.Show Less
Dr. William Fearon graduated from Dartmouth College and received his medical degree from Columbia...Read More
Dr. William Fearon graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow. He is currently a Professor of Cardiology and Director of Interventional Cardiology at Stanford University School of Mediciner. Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation. Dr. Fearon’s primary area of research interest is in coronary physiology. He was the US principal investigator and senior author of the FAME trial, published in the New England Journal of Medicine and was a co-principal investigator and senior author of the FAME 2 trial, also published in the New England Journal of Medicine. He is now the principal investigator of the international FAME 3 trial comparing bypass surgery to fractional flow reserve guided percutaneous coronary intervention. He serves on the editorial board of the Journal of the American College of Cardiology, Circulation, JACC Cardiovascular Interventions, and Circulation: Cardiovascular Interventions. He was the principal investigator on an R01 and is the PI on an R61/R33 NIH award evaluating cardiac allograft vasculopathy early after transplantation. Dr. Fearon’s clinical activities include not only percutaneous coronary intervention, but also transcatheter aortic valve replacement. He was a coauthor on the PARTNER 2A Trial published in the New England Journal of Medicine.Show Less